Balance Sheet
Cash Flow Statement
Capital ExpendituresCash from Financing ActivitiesCash from OperationsCash from RestructuringChange in Account PayablesChange in Accured ExpensesChange in CashDepreciation & Amortization (CF)Depreciation and DepletionFree Cash FlowGains from Investment SecuritiesGains from Sales and DivestituresNet Cash FlowNet IncomeOther financing activitiesShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Lyra Therapeutics (LYRA) Change in Account Payables (2021 - 2025)

Historic Change in Account Payables for Lyra Therapeutics (LYRA) over the last 5 years, with Q3 2025 value amounting to -$120000.0.

  • Lyra Therapeutics' Change in Account Payables rose 9537.04% to -$120000.0 in Q3 2025 from the same period last year, while for Sep 2025 it was -$1.7 million, marking a year-over-year increase of 5980.51%. This contributed to the annual value of -$1.9 million for FY2024, which is 51933.33% down from last year.
  • Lyra Therapeutics' Change in Account Payables amounted to -$120000.0 in Q3 2025, which was up 9537.04% from -$45000.0 recorded in Q2 2025.
  • In the past 5 years, Lyra Therapeutics' Change in Account Payables ranged from a high of $3.3 million in Q1 2023 and a low of -$3.5 million during Q4 2023
  • Over the past 5 years, Lyra Therapeutics' median Change in Account Payables value was -$106000.0 (recorded in 2023), while the average stood at -$111421.1.
  • In the last 5 years, Lyra Therapeutics' Change in Account Payables crashed by 43539.52% in 2022 and then surged by 234339.62% in 2024.
  • Lyra Therapeutics' Change in Account Payables (Quarter) stood at $1.2 million in 2021, then tumbled by 289.69% to -$2.2 million in 2022, then tumbled by 57.53% to -$3.5 million in 2023, then soared by 68.51% to -$1.1 million in 2024, then surged by 89.22% to -$120000.0 in 2025.
  • Its last three reported values are -$120000.0 in Q3 2025, -$45000.0 for Q2 2025, and -$454000.0 during Q1 2025.